Opiant beats path to FDA after nasal overdose drug matches Narcan

Opiant Pharmaceuticals’ opioid overdose drug candidate has held its own against nasal naloxone in a trial of healthy volunteers, giving the company the data it needs to file for approval in the second half of the year.